ASMB
Price
$13.59
Change
-$0.88 (-6.08%)
Updated
May 21 closing price
Capitalization
103.79M
ERAS
Price
$1.22
Change
-$0.06 (-4.69%)
Updated
May 21 closing price
Capitalization
345.61M
77 days until earnings call
Interact to see
Advertisement

ASMB vs ERAS

Header iconASMB vs ERAS Comparison
Open Charts ASMB vs ERASBanner chart's image
Assembly Biosciences
Price$13.59
Change-$0.88 (-6.08%)
Volume$11.72K
Capitalization103.79M
Erasca
Price$1.22
Change-$0.06 (-4.69%)
Volume$547.03K
Capitalization345.61M
ASMB vs ERAS Comparison Chart
Loading...
ASMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASMB vs. ERAS commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASMB is a Buy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (ASMB: $13.59 vs. ERAS: $1.22)
Brand notoriety: ASMB and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASMB: 43% vs. ERAS: 32%
Market capitalization -- ASMB: $103.79M vs. ERAS: $345.61M
ASMB [@Biotechnology] is valued at $103.79M. ERAS’s [@Biotechnology] market capitalization is $345.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASMB’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ASMB’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ASMB is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASMB’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • ASMB’s TA Score: 5 bullish, 4 bearish.
  • ERAS’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ASMB is a better buy in the short-term than ERAS.

Price Growth

ASMB (@Biotechnology) experienced а +12.22% price change this week, while ERAS (@Biotechnology) price change was -3.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.17%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was -1.66%.

Reported Earning Dates

ASMB is expected to report earnings on Mar 20, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($346M) has a higher market cap than ASMB($104M). ASMB YTD gains are higher at: -13.878 vs. ERAS (-51.394). ASMB has higher annual earnings (EBITDA): -44.5M vs. ERAS (-151.33M). ERAS has more cash in the bank: 319M vs. ASMB (91M). ASMB has less debt than ERAS: ASMB (3.02M) vs ERAS (52.9M). ASMB has higher revenues than ERAS: ASMB (32.2M) vs ERAS (0).
ASMBERASASMB / ERAS
Capitalization104M346M30%
EBITDA-44.5M-151.33M29%
Gain YTD-13.878-51.39427%
P/E RatioN/AN/A-
Revenue32.2M0-
Total Cash91M319M29%
Total Debt3.02M52.9M6%
FUNDAMENTALS RATINGS
ASMB: Fundamental Ratings
ASMB
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ASMBERAS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 21 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ASMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JFESX37.99N/A
N/A
JPMorgan Europe Dynamic I
FIAGX21.89N/A
N/A
Fidelity Advisor International Growth A
BUFGX34.39N/A
N/A
Buffalo Growth
KNPCX134.81N/A
N/A
Kinetics Paradigm Adv C
BRZAX12.79-0.09
-0.70%
BlackRock Sus Adg Intl Eq Inv A

ASMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASMB has been loosely correlated with SPRC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ASMB jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASMB
1D Price
Change %
ASMB100%
-6.08%
SPRC - ASMB
45%
Loosely correlated
-8.28%
NKTX - ASMB
42%
Loosely correlated
-5.56%
ALT - ASMB
37%
Loosely correlated
-4.44%
INZY - ASMB
37%
Loosely correlated
N/A
ERAS - ASMB
33%
Loosely correlated
-4.69%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-4.69%
XNCR - ERAS
57%
Loosely correlated
-7.62%
RVMD - ERAS
54%
Loosely correlated
-4.27%
KYMR - ERAS
54%
Loosely correlated
-4.17%
BEAM - ERAS
54%
Loosely correlated
-2.99%
RCKT - ERAS
53%
Loosely correlated
-3.80%
More